A systematic review of GLP-1 agonists on the metabolic syndrome in women with polycystic ovaries.

Glucagon-like peptides receptor agonists are currently approved as anti-obesity agents, yet the experience with their use in polycystic ovarian syndromes (PCOS)-related obesity and insulin resistance is still limited.